The Neurocrine stock has completed its consolidation and is pushing towards the all-time high!

Neurocrine Biosciences remains one of the most exciting biotechnology stocks. This year, the company has made a significantly stronger start with the drug Crenessity than expected, achieving almost $100 million in revenue in the third quarter alone, as analysts had anticipated for the entire year. Due to its high efficacy, it is expected that the company will quickly reach an annual revenue of $1 billion. In addition, the main growth driver INGREZZA shows significant potential, with the company planning to substantially expand its sales team for...